Royalty Pharma plc
Royalty Pharma plc (RPRX) Stock Overview
Explore Royalty Pharma plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
20.6B
P/E Ratio
14.50
EPS (TTM)
$2.45
ROE
0.16%
RPRX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Royalty Pharma plc (RPRX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 61.90, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $28.18.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 14.50 and a market capitalization of 20.6B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.